Amylyx Pharmaceuticals (AMLX) Operating Leases (2022 - 2025)
Historic Operating Leases for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $5.0 million.
- Amylyx Pharmaceuticals' Operating Leases fell 286.27% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 286.27%. This contributed to the annual value of $463000.0 for FY2024, which is 7661.62% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Operating Leases of $5.0 million as of Q3 2025, which was down 286.27% from $5.3 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Operating Leases registered a high of $5.8 million during Q1 2022, and its lowest value of $327000.0 during Q1 2025.
- Moreover, its 4-year median value for Operating Leases was $3.7 million (2023), whereas its average is $3.3 million.
- Per our database at Business Quant, Amylyx Pharmaceuticals' Operating Leases crashed by 7661.62% in 2024 and then soared by 58613.99% in 2025.
- Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Operating Leases stood at $4.2 million in 2022, then crashed by 53.27% to $2.0 million in 2023, then plummeted by 76.62% to $463000.0 in 2024, then surged by 969.98% to $5.0 million in 2025.
- Its Operating Leases stands at $5.0 million for Q3 2025, versus $5.3 million for Q2 2025 and $327000.0 for Q1 2025.